10 Ways Participating In GRIN Helps Support CMT/IN Research

by | Jul 14, 2016 | 0 comments

GrinFB (1)Why should you join GRIN?

It’s pretty simple.

Without you, researchers won’t have the essential patient information to develop the drugs, gene therapy, and clinical trials for Charcot-Marie-Tooth and other Inherited Neuropathies.

HNF’s Global Registry for Inherited Neuropathies (GRIN) is one of our initiatives that supports our commitment and dedication to developing treatments and discovering cures for CMT and other INs.

The registry collects the historical, clinical, and genetic information on patients diagnosed with CMT and the various forms of INs to help advance therapy development for these debilitating disorders.

How does your participation in GRIN help researchers? Here are top ten ways your participation in GRIN helps accelerate research and bring us closer to finding a cure for these diseases:

  1. Your detailed clinical and genetic information will help researchers develop drugs, gene therapy, and clinical trials.
  2. Scientists can learn which genetic modifiers might mitigate the disease using your patient information.
  3. As our registry grows, we gain exponentially wider visibility for researchers into the CMT community and allow more precise targeting of specific conditions.
  4. Researchers can study why individuals have different symptoms.
  5. Scientists can learn about phenotype/genotype relationships, and how a particular mutation type can lead to different or unique symptoms.
  6. Participation in the registry helps researchers learn how future treatments work or don’t work for a given patient population.
  7. Scientists can use tissue samples from registrants who consented to be contacted for such purpose.
  8. Researchers can collaborate with medical professionals to improve how they address the various symptoms for CMT/IN patients.
  9. Researchers can collaborate locally and globally to speed up research processes.
  10. As a registrant, you will be informed when you may be eligible for clinical research studies (clinical trials).

 Ready to join?

Anyone diagnosed with Charcot-Marie-Tooth or a related inherited neuropathy can join our registry. Your information is always kept confidential: only approved PI’s and registry personnel can see your information.

If you are interested in joining our registry, there is no better time than right now. Come join GRIN and be on the front lines to help find the treatments and cures for all inherited neuropathies.

WWW.NEUROPATHYREG.ORG

Learn more on this topic

Related Blog Posts

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Breaking News: First Therapeutic Gene Therapy to Treat an Inherited Neuropathy is Approved for Clinical Trial!

The first disease community to receive a therapeutic gene to the spinal cord for an ultra rare inherited neuropathy is Giant Axonal Neuropathy (GAN). Congratulations to Hannah’s Hope Fund (HHF), a 501(c)3 public charity, which has driven this collaborative research in less than six years. Six million dollars has been raised to date to fund pre-clinical and clinical research on this rare disease.

A Rare Disease Patient That Does It All!

A movie script could not play out like this. There are very few occasions when a rare disease patient becomes the topic of a story that is truly uplifting. Often the stories are tragic or disheartening. That was not the case, however, with CMT patient Kim Goodsell.

Hot Off the Press

One of the ways that some CMT patients first become aware of their disease is when they are given a drug treatment for another disease. This is termed chemotherapy-induced neurotoxicity. Drugs such as paclitaxel and the vinca alkaloids that are widely used in cancer treatment cause severe peripheral neuropathy and in some patients this exacerbates CMT, revealing it perhaps for the first time.

Kara Q&A: How to “support” a friend or family member that’s affected with Charcot-MarieTooth.

My name is Courtney Hollett, Fundraising Coordinator at the Hereditary Neuropathy Foundation. This time of year I count my blessing daily and wanted to share with you a Q&A session I had with a new supporter of HNF. Kara, like myself has many family members affected with CMT and I reached out to her to share her thoughts and advice about how to “support” a friend or family member that’s affected with Charcot-MarieTooth.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news